Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Rating of “Hold” from Analysts

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have received a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $32.00.

Several brokerages have issued reports on FLGT. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Zacks Research downgraded shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Finally, Wall Street Zen lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Hedge Funds Weigh In On Fulgent Genetics

A number of large investors have recently modified their holdings of FLGT. Caitong International Asset Management Co. Ltd boosted its stake in shares of Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after buying an additional 1,251 shares in the last quarter. XTX Topco Ltd grew its holdings in Fulgent Genetics by 33.1% during the fourth quarter. XTX Topco Ltd now owns 22,195 shares of the company’s stock worth $583,000 after acquiring an additional 5,523 shares during the period. Susquehanna Portfolio Strategies LLC raised its position in Fulgent Genetics by 13.4% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 38,480 shares of the company’s stock worth $1,011,000 after acquiring an additional 4,560 shares in the last quarter. RTW Investments LP acquired a new stake in Fulgent Genetics in the fourth quarter valued at $18,521,000. Finally, Oxford Asset Management LLP acquired a new stake in Fulgent Genetics in the fourth quarter valued at $254,000. 48.06% of the stock is owned by hedge funds and other institutional investors.

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT opened at $16.82 on Friday. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04. The stock has a market capitalization of $500.40 million, a price-to-earnings ratio of -8.58 and a beta of 0.89. The company has a 50-day simple moving average of $19.90 and a 200-day simple moving average of $23.74.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, February 27th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, research analysts forecast that Fulgent Genetics will post -0.85 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.